{"analyses":[{"ciLowerLimit":"0.376","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.620","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.483","statisticalComment":"Stratified Log-Rank Test and HR stratified by randomization strata (weight loss over the prior 3 months, primary tumor site and geographical region).","statisticalMethod":"Stratified Log-Rank Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.7","value":"2.1"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"1.4","value":"1.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"description":"PFS is defined as the time from date of randomization until date of objectively determined progressive disease (PD) or death due to any cause, whichever is first. Participants alive and without PD were censored at the time of last adequate objective tumor assessment (that is, response other than unevaluable).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMC-1121B (ramucirumab), administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), plus best supportive care (BSC) as determined by the investigator(s). Treatment continued until there was evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.","id":"OG000","title":"IMC-1121B (Ramucirumab)"},{"description":"Participants received placebo by intravenous infusion every 2 weeks plus best supportive care as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel were blinded as to assignment to active therapy versus placebo, the volume of placebo administered was calculated as if it were active product with a dose of 8 mg/kg. Treatment continued until there was evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population: all randomized participants. Censored participants: ramucirumab=39, placebo=9.","reportingStatus":"POSTED","timeFrame":"Randomization up to 17 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}